BIOCON LTD has announced its results for the quarter ended September 2018. Here is a detailed performance review of the same:
No. of Mths Qtr. Ending | 3 Sep-17* | 3 Jun-18* | 3 Sep-18* | QoQ Change | YoY Change | |
---|---|---|---|---|---|---|
Net Sales | Rs m | 9,686 | 11,238 | 13,210 | 17.5% | 36.4% |
Other income | Rs m | 508 | 688 | 544 | -20.9% | 7.1% |
Turnover | Rs m | 10,194 | 11,926 | 13,754 | 15.3% | 34.9% |
Expenses | Rs m | 7,863 | 8,860 | 9,814 | 10.8% | 24.8% |
Gross profit | Rs m | 1,620 | 2,378 | 5,284 | 122.2% | 226.2% |
Depreciation | Rs m | 936 | 991 | 1,122 | 13.2% | 19.9% |
Interest | Rs m | 138 | 176 | 188 | 6.8% | 36.2% |
Profit before tax | Rs m | 1,054 | 1,899 | 4,518 | 137.9% | 328.7% |
Tax | Rs m | 425 | 521 | 732 | 40.5% | 72.2% |
Profit after tax | Rs m | 629 | 1,378 | 3,786 | 174.7% | 501.9% |
Gross profit margin | % | 16.7 | 21.2 | 40.0 | ||
Effective tax rate | % | 40.3 | 27.4 | 16.2 | ||
Net profit margin | % | 6.2 | 11.6 | 27.5 |
To see how BIOCON LTD has performed over the last eight quarters, please visit here.
Over the last one year, BIOCON LTD share price has moved up from Rs 400.7 to Rs 636.5, registering a Gain of Rs 235.9 or around 58.9%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,681.6 (up 1.0%). Over the last one year it has moved up from 13,987.8 to 14,681.6, a gain of 694 points (up 5.0%).
Overall, the S&P BSE SENSEX is up 5.3% over the year.
At the current price of Rs 636.5, the price to earnings (P/E) ratio of BIOCON LTD stands at 50.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 7.4 times.
| |
For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsA single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
This one trade had my subscribers laughing all the way to the bank.
What we can learn from one of the greatest traders to have ever lived.
Should you invest in growth stocks or value stocks to make strong returns in this market?
The two trends that are playing out as Sensex touches new record high.
More
| |
Equitymaster requests your view! Post a comment on "BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!